SPTX Earnings Date: Nov 2, 2026 (Estimated) — Seaport Therapeutics, Inc. Common Stock

NASDAQ · Healthcare · Biotechnology

Updated Oct 30, 2026

Price $19.98

Market Cap $1.1B

P/E -12.5

52W Range $14.85 – $28.38

Next Earnings Nov 2, 2026 (est.)

When is SPTX's next earnings date?

Seaport Therapeutics, Inc. Common Stock (SPTX) is expected to report earnings on Monday, November 2, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.58.

How did SPTX do in its last earnings report?

In its most recent report on Aug 3, 2026 (Q2 2026), Seaport Therapeutics, Inc. Common Stock posted EPS of -$1.78 versus the -$0.60 estimate, a miss of 196.7%. Revenue was $0. The stock's 1-day post-earnings move was +0.9%.

How much does SPTX stock move after earnings?

SPTX beat EPS estimates in 1 of its last 2 reported quarters. Over the last 2 reports the stock moved an average of 1.2% (up or down) in the day after earnings.

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.